Upstate Active Clinical Trials

Study Title:

ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma

What is the purpose of the study?

This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers. It is not yet known whether ipilimumab is more effective than interferon alfa-2b in treating patients with melanoma.

Upstate Institutional Review Board (IRB) Number:

275505

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

ClinicalTrials.Gov ID:

NCT01274338

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Virginia M Schutt, CCRP
Phone: 315-464-8230
Email: schuttg@upstate.edu

Return to Previous Page || Search Again